Friday, 21 Sep 2018

You are here

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Studies have shown that the risk of major cardiovascular events (MACE) is elevated and not significantly different between RA and AxSpa or PsA (http://bit.ly/2MoHFNs).

A total of 4140 consecutive patients from the Australian Rheumatology Association Database with RA, PsA and AS, were followed between September 2001 to January 2015 and were included in the study.

An analysis of 19,627 patient-years showed that (after multivariate adjustment) the CVE risk was lower with TNFI (HR 0.85, 95% CI 0.76–0.95) and other biologic therapies (HR 0.81, 95% CI 0.70–0.95), but not in those who had stopped their biologic agents (HR 0.96, 95% CI 0.83–1.11). CVE risk was the same between RA, PsA and AS patients. 

These studies are similar to other showing the protective CV benefits of sustained therapy with either methotrexate or TNFi. 

This is important as a recent claims database study of 10,254 patients with RA, PsA, or Psoriasis seen between 2006-2015 showed that after initial CV event 15.3% discontinued and 15.5% switched DMARD therapy after index CV event. Independent predictors of DMARD discontinuation included PsO diagnosis, renal disease, hypertension, heart failure, diabetes mellitus, older age, and baseline csDMARD or non-TNFi bDMARD use (vs TNFi bDMARDs).  (http://bit.ly/2nzKeOs)

In their study, having RA and heart failure at baseline, but not DMARD use after index event, were independently associated with increased risk of a subsequent CV event.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target in RA: No Increase in AEs

Implementing a treat-to-target approach for the care of rheumatoid arthritis (RA) did not result in an increase in adverse events or resource use, a post-hoc analysis of a randomized trial showed.

Mediterranean Diet Reduces Risk of Rheumatoid Arthritis

High adherence to a Mediterranean diet appears to be associated with a lower risk of rheumatoid arthritis (RA), especially in men and those who are seropositive, according to a study published in Arthritis Research & Therapy.

Early Exposure to Passive Smoke May Up Risk for RA Later in Life

Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Maternal RA Increases Offspring Risk of Autoimmune Disorders

A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.